[go: up one dir, main page]

WO2024120378A3 - Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci - Google Patents

Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci Download PDF

Info

Publication number
WO2024120378A3
WO2024120378A3 PCT/CN2023/136398 CN2023136398W WO2024120378A3 WO 2024120378 A3 WO2024120378 A3 WO 2024120378A3 CN 2023136398 W CN2023136398 W CN 2023136398W WO 2024120378 A3 WO2024120378 A3 WO 2024120378A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation methods
triazole compounds
medicinal uses
compounds
wrn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2023/136398
Other languages
English (en)
Other versions
WO2024120378A2 (fr
Inventor
Hugh Y. Zhu
Xinlin Du
Gang Liu
Jason Rohde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Hansoh Bio LLC
Original Assignee
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Shanghai Hansoh Biomedical Co Ltd
Hansoh Bio LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd, Hansoh Bio LLC filed Critical Jiangsu Hansoh Pharmaceutical Group Co Ltd
Priority to EP23899953.6A priority Critical patent/EP4630426A2/fr
Priority to CN202380081388.XA priority patent/CN120265634A/zh
Publication of WO2024120378A2 publication Critical patent/WO2024120378A2/fr
Publication of WO2024120378A3 publication Critical patent/WO2024120378A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des composés de formules (I) utiles en tant qu'inhibiteurs de WRN, leur procédé de préparation, des compositions pharmaceutiques comprenant les composés, et des utilisations pharmaceutiques pour le traitement de maladies ou de troubles à médiation par WRN.
PCT/CN2023/136398 2022-12-05 2023-12-05 Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci Ceased WO2024120378A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP23899953.6A EP4630426A2 (fr) 2022-12-05 2023-12-05 Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci
CN202380081388.XA CN120265634A (zh) 2022-12-05 2023-12-05 三唑化合物、其制备方法和医药用途

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202263386066P 2022-12-05 2022-12-05
US63/386066 2022-12-05
US202363483134P 2023-02-03 2023-02-03
US63/483134 2023-02-03
US202363491803P 2023-03-23 2023-03-23
US63/491803 2023-03-23
US202363497827P 2023-04-24 2023-04-24
US63/497827 2023-04-24

Publications (2)

Publication Number Publication Date
WO2024120378A2 WO2024120378A2 (fr) 2024-06-13
WO2024120378A3 true WO2024120378A3 (fr) 2024-07-11

Family

ID=91378578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/136398 Ceased WO2024120378A2 (fr) 2022-12-05 2023-12-05 Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci

Country Status (3)

Country Link
EP (1) EP4630426A2 (fr)
CN (1) CN120265634A (fr)
WO (1) WO2024120378A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024193716A1 (fr) * 2023-03-17 2024-09-26 南京再明医药有限公司 Composé de triazolopyrimidine
TW202444720A (zh) * 2023-03-23 2024-11-16 大陸商北京丹擎醫藥科技有限公司 雙環衍生物，及其組合物和應用
TW202502345A (zh) 2023-06-08 2025-01-16 美商林伯士瓦吉特公司 Wrn抑制劑
WO2024259048A2 (fr) * 2023-06-13 2024-12-19 Nimbus Wadjet, Inc. Inhibiteurs de thiazolopyridin-7(4h)-one wrn
TW202504593A (zh) * 2023-06-15 2025-02-01 大陸商勤浩醫藥(蘇州)有限公司 稠環化合物、包含其的藥物組合物及其用途
WO2025021148A1 (fr) * 2023-07-27 2025-01-30 贝达药业股份有限公司 Inhibiteur de wrn, composition pharmaceutique associée et utilisation associée
WO2025073792A1 (fr) 2023-10-02 2025-04-10 Forx Therapeutics Ag Composés inhibiteurs de wrn
WO2025087274A1 (fr) * 2023-10-27 2025-05-01 浙江海正药业股份有限公司 Dérivé azabicyclo, son procédé de préparation et son utilisation
WO2025152932A1 (fr) * 2024-01-15 2025-07-24 上海齐鲁制药研究中心有限公司 Dérivé de triazolopyrimidine, son procédé de préparation et son utilisation
WO2025161791A1 (fr) * 2024-02-01 2025-08-07 福石生物科技(合肥)有限公司 Dérivé spiro servant d'inhibiteur de wrn et utilisation d'un dérivé spiro
CN120424093A (zh) * 2024-02-02 2025-08-05 中国科学院上海药物研究所 螺环类化合物、包含其的药物组合物及其用途
WO2025215527A2 (fr) 2024-04-10 2025-10-16 Novartis Ag Combinaisons pharmaceutiques et leurs utilisations

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528754A (zh) * 2006-08-29 2009-09-09 波士顿大学信托人 使用结合wrn的分子的治疗方法
CN102439011A (zh) * 2009-02-11 2012-05-02 加利福尼亚大学校务委员会 Toll样受体调节剂和疾病的治疗
US20160002247A1 (en) * 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
WO2022249060A1 (fr) * 2021-05-26 2022-12-01 Novartis Ag Analogues de triazolo-pyrimidine pour le traitement de maladies liées à l'inhibition de l'hélicase recq du syndrome de werner (wrn)

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101528754A (zh) * 2006-08-29 2009-09-09 波士顿大学信托人 使用结合wrn的分子的治疗方法
CN102439011A (zh) * 2009-02-11 2012-05-02 加利福尼亚大学校务委员会 Toll样受体调节剂和疾病的治疗
US20160002247A1 (en) * 2013-03-01 2016-01-07 The University Of Tokyo 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity
WO2022249060A1 (fr) * 2021-05-26 2022-12-01 Novartis Ag Analogues de triazolo-pyrimidine pour le traitement de maladies liées à l'inhibition de l'hélicase recq du syndrome de werner (wrn)

Also Published As

Publication number Publication date
WO2024120378A2 (fr) 2024-06-13
CN120265634A (zh) 2025-07-04
EP4630426A2 (fr) 2025-10-15

Similar Documents

Publication Publication Date Title
WO2024120378A3 (fr) Composés de triazole, procédés de préparation et utilisations médicinales de ceux-ci
WO2003053368A3 (fr) Derives de chalcone et leur utilisation dans le traitement de maladies
HUP0104718A2 (hu) Mikronizált eplerenon kompozíciók és eljárás az előállításukra
MX2023003627A (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer.
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20083958L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
WO2022268935A3 (fr) Nouveau procédé
WO2024006726A3 (fr) Composés utilisés en tant qu'inhibiteurs d'axl
WO2023150619A3 (fr) Tétrahydropyridopyrimidines et analogues associés pour inhiber yap/taz-tead
WO2024167922A3 (fr) Composés hétérocycliques utilisés en tant qu'inhibiteurs de nras
WO2023205463A8 (fr) Composés hétéroaryles pour le traitement de la douleur
WO2022106902A8 (fr) Dérivés de benzènesulfonamide et leurs utilisations
WO2024215862A3 (fr) Composés hétérocycliques en tant qu'inhibiteurs de nras
WO2024026481A3 (fr) Inhibiteurs de cdk2 et leurs procédés d'utilisation
WO2024086789A3 (fr) Inhibiteurs de pi3k-alpha mutants et leur utilisation en tant que produits pharmaceutiques
WO2020154420A3 (fr) Dérivés d'acides aminés pour le traitement de maladies inflammatoires
CA3242600A1 (fr) Procedes pour la preparation de derives de 1,2,3,5,6,7-hexahydro-s-indacene
WO2023150790A3 (fr) Nouveaux inhibiteurs mpro du sars-cov-2 hautement sélectifs
WO2024026129A3 (fr) Dérivés aryle tricycliques, et compositions et procédés associés
WO2023168246A3 (fr) Inhibiteurs sélectifs de la kinase 5 du récepteur couplé à la protéine g, compositions et procédés d'utilisation
WO2004072037A8 (fr) Derives de 2,3'-bipyridines servant d'inhibiteurs de cox-2 selectifs
TW202547477A (zh) 大環化合物、其製備方法及醫藥用途
WO2004108094A3 (fr) Derives de chalcone substitues par sulfonamide
WO2025188658A8 (fr) Modulateurs d'akt1
WO2024086814A3 (fr) Inhibiteurs de cycline

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23899953

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380081388.X

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2025531115

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2025531115

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 202380081388.X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2023899953

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023899953

Country of ref document: EP

Effective date: 20250707

WWP Wipo information: published in national office

Ref document number: 2023899953

Country of ref document: EP